The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE., J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8., 2011 Jan 01

Abstract

This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends.

I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry.

I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

Related Publications

Physicians’ well-being linked to in-basket messages generated by algorithms In EHRs.

Tai-Seale M, Dillon EC, Yang Y, Nordgren R, Steinberg R, Nauenberg T, Lee TC, Meehan A, Li J, Chan AS, Frosch D.
Health Aff. 38(7): https://doi.org/10.1377/hlthaff.2018.05509.
2019 Jul 01

Physicians’ well-being linked to in-basket messages generated by algorithms In electronic health records.

Tai-Seale M, Dillon EC, Yang Y, Nordgren R, Steinberg R, Nauenberg T, Lee TC, Meehan A, Li J, Chan AS, Frosch D.
Health Aff. 38(7): https://doi.org/10.1377/hlthaff.2018.05509.
2019 Jul 01

Comparative usability study of a newly created patient-centered tool and Medicare.gov plan finder to help Medicare beneficiaries choose prescription drug plans.

Stults CD, Fattahi S, Meehan A, Bundorf MK, Chan AS, Pun T, Tai-Seale M.
J Patient Exp. 6(1):81-86. doi: 10.1177/2374373518778343. Epub 2018 Jun 6.
2019 Mar 01

Measuring adherence and outcomes in the treatment of patients with multiple sclerosis.

Hao J, Pitcavage J, Jones JB, Hoegerl C, Graham J.
J Am Osteopath Assoc. 117(12):737-747. doi: 10.7556/jaoa.2017.145.
2017 Dec 01

Medication burden in patients with acute coronary syndromes.

Wright EA, Steinhubl SR, Jones JB, Barua P, Yan X, Van Loan R, Frederick G, Bhandary D, Cobden D.
Am J Manag Care. 2017 Apr 1;23(4):e106-e112.
2017 Apr 01